{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:53:33Z","timestamp":1792086813818,"version":"4.4.0"},"reference-count":21,"publisher":"Walter de Gruyter GmbH","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,8,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_pp-2017-0018_s_010_w2aab3b7c13b1b6b1aab1c16b1Aa\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pressurized intraperitoneal aerosol chemotherapy (PIPAC) has emerged as a novel method to treat extensive, small volume peritoneal metastases. The clinical use of chemotherapy containing aerosols represents a potential occupational health hazard. We report the results of toxicological analysis during the first two clinical PIPAC procedures performed at Ghent University Hospital.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2017-0018_s_011_w2aab3b7c13b1b6b1aab1c16b2Aa\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      After extensive preparation and\n                      <jats:italic>in vitro<\/jats:italic>\n                      testing, two patients were treated with PIPAC: the first using doxorubicin (2.86\u2006mg in 51.43 mL) and cisplatin (14.28\u2006mg in 164.3 mL), the second using oxaliplatin (182.10\u2006mg in 186.42 mL). A standardized safety checklist was developed and used. Aerosol delivery was combined with electrostatic precipitation (ePIPAC). The following samples were obtained at several time points and locations: environmental air, floor surface wipes, surgeon\u2019s gloves, surgeon\u2019s hand wipes, circuit filters, and fluid from the water seal collection chamber container placed along the closed aerosol waste evacuating line. Platinum concentration was measured in these samples using voltammetry. Sample collection and analysis were performed by an independent external laboratory.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2017-0018_s_012_w2aab3b7c13b1b6b1aab1c16b3Aa\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Platinum was not detected on the four floor locations after both procedures (detection limit 0.02 ng\/cm\n                      <jats:sup>2<\/jats:sup>\n                      ). Similarly, no platinum was detected in environmental air during both PIPACs at the surgeon\u2019s or anesthesiologist\u2019s position (detection limit 4.0\u201327 ng\/m\n                      <jats:sup>3<\/jats:sup>\n                      ). No platinum contamination was detected on the hands, outer pair of gloves, or inner pair of gloves of the surgeon (detection limit 70 and 50 ng respectively). Platinum was not detected on the filters and in the air-seal container liquid.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2017-0018_s_013_w2aab3b7c13b1b6b1aab1c16b4Aa\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>With adequate preparation and precautions, a clinical PIPAC program can be established without measurable chemotherapy exposure to the operating room environment or healthcare workers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/pp-2017-0018","type":"journal-article","created":{"date-parts":[[2017,8,12]],"date-time":"2017-08-12T06:01:43Z","timestamp":1502517703000},"page":"121-128","source":"Crossref","is-referenced-by-count":31,"title":["Occupational safety of pressurized intraperitoneal aerosol chemotherapy (PIPAC)"],"prefix":"10.1515","volume":"2","author":[{"given":"Wouter","family":"Willaert","sequence":"first","affiliation":[{"name":"Department of GI Surgery , Ghent University Hospital , route 1275, De Pintelaan 185, 9000 , Ghent , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sessink","sequence":"additional","affiliation":[{"name":"Exposure Control Sweden AB , Bohus-Bj\u00f6rk\u00f6 , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Ceelen","sequence":"additional","affiliation":[{"name":"Department of GI Surgery , Ghent University Hospital , route 1275, De Pintelaan 185, 9000 , Ghent , Belgium"},{"name":"Cancer research institute Ghent (CRIG) , Ghent , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2017,8,12]]},"reference":[{"key":"2025120909192905307_j_pp-2017-0018_ref_001_w2aab3b7c13b1b6b1ab2b2b1Aa","doi-asserted-by":"crossref","unstructured":"Segelman J, Granath F, Holm T, Machado M, Mahteme H, Martling A. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg 2012;99:699\u2013705.","DOI":"10.1002\/bjs.8679"},{"key":"2025120909192905307_j_pp-2017-0018_ref_002_w2aab3b7c13b1b6b1ab2b2b2Aa","doi-asserted-by":"crossref","unstructured":"Thomassen I, Van Gestel YR, van Ramshorst B, Luyer MD, Bosscha K, Nienhuijs SW et al. Peritoneal carcinomatosis of gastric origin: A population-based study on incidence, survival and risk factors. Int J Cancer 2014;134:622\u2013628.","DOI":"10.1002\/ijc.28373"},{"key":"2025120909192905307_j_pp-2017-0018_ref_003_w2aab3b7c13b1b6b1ab2b2b3Aa","doi-asserted-by":"crossref","unstructured":"Thomassen I, Ve L, Sw N, Luyer MD, Yl K, Ih DH. Incidence, prognosis, and possible treatment strategies of peritoneal carcinomatosis of pancreatic origin: A population-based study. Pancreas 2013;42:72\u201375.","DOI":"10.1097\/MPA.0b013e31825abf8c"},{"key":"2025120909192905307_j_pp-2017-0018_ref_004_w2aab3b7c13b1b6b1ab2b2b4Aa","unstructured":"Van Driel W, Sikorska K, Schagen van Leeuwen J, Schreuder H, Hermans R, de Hingh I et al. A phase 3 trial of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer. J Clin Oncol 2017;35(suppl; abstr 5519)."},{"key":"2025120909192905307_j_pp-2017-0018_ref_005_w2aab3b7c13b1b6b1ab2b2b5Aa","unstructured":"Dehal A, Smith JJ, Nash GM. Cytoreductive surgery and intraperitoneal chemotherapy: An evidence-based review-past, present and future. J Gastrointest Oncol 2016;7:143\u2013157."},{"key":"2025120909192905307_j_pp-2017-0018_ref_006_w2aab3b7c13b1b6b1ab2b2b6Aa","doi-asserted-by":"crossref","unstructured":"Baratti D, Kusamura S, Pietrantonio F, Guaglio M, Niger M, Deraco M. Progress in treatments for colorectal cancer peritoneal metastases during the years 2010\u20132015. Syst Rev Crit Rev Oncol Hematol 2016;100:209\u2013222.","DOI":"10.1016\/j.critrevonc.2016.01.017"},{"key":"2025120909192905307_j_pp-2017-0018_ref_007_w2aab3b7c13b1b6b1ab2b2b7Aa","doi-asserted-by":"crossref","unstructured":"Wu Z, Li Z, Ji J. Morbidity and mortality of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in advanced gastric cancer. Transl Gastroenterol Hepatol 2016;1:63.","DOI":"10.21037\/tgh.2016.07.03"},{"key":"2025120909192905307_j_pp-2017-0018_ref_008_w2aab3b7c13b1b6b1ab2b2b8Aa","doi-asserted-by":"crossref","unstructured":"Solass W, Hetzel A, Nadiradze G, Sagynaliev E, Reymond MA. Description of a novel approach for intraperitoneal drug delivery and the related device. Surg Endosc 2012;26:1849\u20131855.","DOI":"10.1007\/s00464-012-2148-0"},{"key":"2025120909192905307_j_pp-2017-0018_ref_009_w2aab3b7c13b1b6b1ab2b2b9Aa","unstructured":"Tempfer CB, Rezniczek GA, Ende P, Solass W, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin in women with peritoneal carcinomatosis: A cohort study. Anticancer Res 2015;35:6723\u20136729."},{"key":"2025120909192905307_j_pp-2017-0018_ref_010_w2aab3b7c13b1b6b1ab2b2c10Aa","doi-asserted-by":"crossref","unstructured":"Demtroder C, Solass W, Zieren J, Strumberg D, Giger-Pabst U, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis. Colorectal Dis 2016;18:364\u2013371.","DOI":"10.1111\/codi.13130"},{"key":"2025120909192905307_j_pp-2017-0018_ref_011_w2aab3b7c13b1b6b1ab2b2c11Aa","doi-asserted-by":"crossref","unstructured":"Grass F, Vuagniaux A, Teixeira-Farinha H, Lehmann K, Demartines N, Hubner M. Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis. Br J Surg 2017;104:669\u2013678.","DOI":"10.1002\/bjs.10521"},{"key":"2025120909192905307_j_pp-2017-0018_ref_012_w2aab3b7c13b1b6b1ab2b2c12Aa","doi-asserted-by":"crossref","unstructured":"Kakchekeeva T, Demtroder C, Herath NI, Griffiths D, Torkington J, Solass W et al. In vivo feasibility of electrostatic precipitation as an adjunct to pressurized intraperitoneal aerosol chemotherapy (ePIPAC). Ann Surg Oncol 2016;23:592\u2013598.","DOI":"10.1245\/s10434-016-5108-4"},{"key":"2025120909192905307_j_pp-2017-0018_ref_013_w2aab3b7c13b1b6b1ab2b2c13Aa","doi-asserted-by":"crossref","unstructured":"Reymond M, Demtroeder C, Solass W, Winnekendonk G, Tempfer C. Electrostatic precipitation pressurized intraperitoneal aerosol chemotherapy (ePIPAC): First in-human application. Pleura and Peritoneum 2016;1:109\u2013116.","DOI":"10.1515\/pp-2016-0005"},{"key":"2025120909192905307_j_pp-2017-0018_ref_014_w2aab3b7c13b1b6b1ab2b2c14Aa","doi-asserted-by":"crossref","unstructured":"Solass W, Giger-Pabst U, Zieren J, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC): Occupational health and safety aspects. Ann Surg Oncol 2013;20:3504\u20133511.","DOI":"10.1245\/s10434-013-3039-x"},{"key":"2025120909192905307_j_pp-2017-0018_ref_015_w2aab3b7c13b1b6b1ab2b2c15Aa","doi-asserted-by":"crossref","unstructured":"Graversen M, Pedersen PB, Mortensen MB. Environmental safety during the administration of pressurized intraperitoneal aerosol chemotherapy (PIPAC). Pleura and Peritoneum 2016;1:203\u2013208.","DOI":"10.1515\/pp-2016-0019"},{"key":"2025120909192905307_j_pp-2017-0018_ref_016_w2aab3b7c13b1b6b1ab2b2c16Aa","doi-asserted-by":"crossref","unstructured":"Kyriazanos I, Kalles V, Stefanopoulos A, Spiliotis J, Mohamed F. Operating personnel safety during the administration of hyperthermic intraperitoneal chemotherapy (HIPEC). Surg Oncol 2016;25:308\u2013314.","DOI":"10.1016\/j.suronc.2016.06.001"},{"key":"2025120909192905307_j_pp-2017-0018_ref_017_w2aab3b7c13b1b6b1ab2b2c17Aa","doi-asserted-by":"crossref","unstructured":"Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F, Bouvard V, et al. A review of human carcinogens\u2013Part A: Pharmaceuticals. Lancet Oncol 2009;10:13\u201314.","DOI":"10.1016\/S1470-2045(08)70286-9"},{"key":"2025120909192905307_j_pp-2017-0018_ref_018_w2aab3b7c13b1b6b1ab2b2c18Aa","doi-asserted-by":"crossref","unstructured":"Villarini M, Gianfredi V, Levorato S, Vannini S, Salvatori T, Moretti M. Occupational exposure to cytostatic\/antineoplastic drugs and cytogenetic damage measured using the lymphocyte cytokinesis-block micronucleus assay: A systematic review of the literature and meta-analysis. Mutat Res 2016;770:35\u201345.","DOI":"10.1016\/j.mrrev.2016.05.001"},{"key":"2025120909192905307_j_pp-2017-0018_ref_019_w2aab3b7c13b1b6b1ab2b2c19Aa","doi-asserted-by":"crossref","unstructured":"Villa AF, El Balkhi S, Aboura R, Sageot H, Hasni-Pichard H, Pocard M, et al. Evaluation of oxaliplatin exposure of healthcare workers during heated intraperitoneal perioperative chemotherapy (HIPEC). Ind Health 2015;53:28\u201337.","DOI":"10.2486\/indhealth.2014-0025"},{"key":"2025120909192905307_j_pp-2017-0018_ref_020_w2aab3b7c13b1b6b1ab2b2c20Aa","unstructured":"NIOSH list of antineoplastic and other hazardous drugs in healthcare settings, 2016. https:\/\/www.cdc.gov\/niosh\/docs\/2016-161\/pdfs\/2016-161.pdf [last accessed May 27, 2017]."},{"key":"2025120909192905307_j_pp-2017-0018_ref_021_w2aab3b7c13b1b6b1ab2b2c21Aa","unstructured":"Landeck L, Gonzalez E, Koch OM. Handling chemotherapy drugs-Do medical gloves really protect? Int J Cancer 2015;137:1800\u20131805."}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/pp\/2\/3\/article-p121.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2017-0018\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2017-0018\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T09:56:49Z","timestamp":1765274209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2017-0018\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,12]]},"references-count":21,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,9,1]]},"published-print":{"date-parts":[[2017,8,31]]}},"alternative-id":["10.1515\/pp-2017-0018"],"URL":"https:\/\/doi.org\/10.1515\/pp-2017-0018","relation":{},"ISSN":["2364-768X","2364-7671"],"issn-type":[{"value":"2364-768X","type":"electronic"},{"value":"2364-7671","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8,12]]}}}